Extended-release niacin/lovastatin: the first combination product for dyslipidemia

Expert Review of Cardiovascular Therapy
Harold E Bays

Abstract

Many clinical studies have demonstrated that lipid-altering drug treatments, including the use of statin and niacin monotherapy, can be effective in the primary and secondary prevention of coronary heart disease, but only in a minority of patients relative to placebo. Since statins and niacin have entirely different mechanisms of action and predominantly different effects on blood lipid levels, the combined use of both a statin and niacin may confer complementary benefits on multiple lipid parameters, produce a more global improvement in lipid blood levels and result in greater reductions in coronary heart disease risk factors than the administration of either agent alone. This may be of particular importance in patients with complex dyslipidemias, such as those with Type 2 diabetes mellitus and metabolic syndrome. This review summarizes the efficacy and safety of extended-release niacin/lovastatin (Advicor, Kos Pharmaceuticals Inc.), the first combination product approved for the management of dyslipidemia.

References

Jan 27, 1975·JAMA : the Journal of the American Medical Association
Feb 1, 1991·Circulation·D H BlankenhornE C Wickham
Dec 19, 1990·JAMA : the Journal of the American Medical Association·J P KaneR J Havel
Dec 19, 1990·JAMA : the Journal of the American Medical Association·L Cashin-HemphillD H Blankenhorn
Jun 19, 1987·JAMA : the Journal of the American Medical Association·D H BlankenhornL Cashin-Hemphill
Dec 1, 1986·Journal of the American College of Cardiology·P L CannerW Friedewald
Nov 15, 1993·Annals of Internal Medicine·D H BlankenhornUNKNOWN MARS Research Group
Feb 1, 1996·Cardiology Clinics·D Waters
Jun 5, 1998·JAMA : the Journal of the American Medical Association·R S Rosenson, C C Tangney
Dec 5, 1998·The New England Journal of Medicine·UNKNOWN Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
Dec 21, 2000·Current Atherosclerosis Reports·V S Kamanna, M L Kashyap
Dec 21, 2000·Current Atherosclerosis Reports·D M CapuzziC M Intenzo
Jan 5, 2002·The New England Journal of Medicine·B G BrownJ J Albers
Feb 19, 2002·The Annals of Pharmacotherapy·Mohamed A Omar, James P Wilson
Mar 19, 2002·The American Journal of Cardiology·Moti L KashyapPhillip D Simmons
Jun 14, 2002·The American Journal of Cardiology·Keith G Tolman
Jul 3, 2002·Circulation·David R Holmes, Bernard J Gersh
Jul 11, 2002·The American Journal of Cardiology·Frank M Sacks, UNKNOWN Expert Group on HDL Cholesterol
Jul 27, 2002·Journal of the American College of Cardiology·Richard C PasternakUNKNOWN National Heart, Lung and Blood Institute
Nov 20, 2002·Expert Opinion on Investigational Drugs·Harold Bays
Nov 30, 2002·Lancet·James ShepherdUNKNOWN PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk
Dec 7, 2002·The American Journal of Cardiology·Antonios M Xydakis, Christie M Ballantyne
Dec 11, 2002·Expert Opinion on Pharmacotherapy·Yong S K Moon, Moti L Kashyap
Jan 11, 2003·The Journal of Biological Chemistry·Alan WiseNicholas B Pike
Feb 4, 2003·Nature Medicine·Sorin TunaruStefan Offermanns
Mar 14, 2003·The American Journal of Cardiology·Harold E BaysUNKNOWN ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation

❮ Previous
Next ❯

Citations

Sep 26, 2009·Current Opinion in Lipidology·Harold E Bays, Christie Ballantyne
Jan 1, 2005·Future Cardiology·Harold BaysManisha Chandalia
Sep 27, 2005·Expert Review of Cardiovascular Therapy·Harold BaysMichael Davidson
Apr 22, 2005·Postgraduate Medicine·Mark E McGovern
Oct 22, 2008·Expert Opinion on Pharmacotherapy·Karam Kostner, Soneil Gupta
Mar 21, 2007·The American Journal of Cardiology·John R Guyton, Harold E Bays
Apr 4, 2006·The American Journal of Cardiology·Harold Bays
Jun 14, 2008·The American Journal of Cardiology·Harold Bays
May 20, 2015·International Journal of Pharmaceutics·Dustin L CooperSam Harirforoosh
Dec 20, 2007·American Journal of Therapeutics·Harold E Bays, Ronald B Goldberg

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.